1 Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 The news made me sad as I found her career path quite inspiring And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow.". We believe that success of our science is measured by the lives we touch. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares . Engage with instructors and fellow students for half-day or up to three-day programs in a virtual or classroom setting. Bristol-Myers Squibb had a positive return on equity of 33.76% and a negative net margin of 14.53%. Bristol Myers (BMY) Earnings Date & Reports 8,681 Followers Portfolio Earnings Data Report Date Apr 27, 2023 Before Open Not Confirmed Period Ending 2023 (Q1) Consensus EPS Forecast $1.98 Last Year's EPS $1.96 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 9 Analysts Ratings Bristol Myers (BMY) Earnings, Revenues Date & History In celebration of the five generations that make up our workforce, we offer benefits to help you through every stage and milestone of life. Your response will be removed from the review this cannot be undone. By Tina Bellon and Nate Raymond. 0000115702 00000 n The same period a year ago included license and acquisition charges related to Dragonfly, an in-process research and development (IPR&D) impairment charge and cash settlement of MyoKardia unvested stock awards. Bristol Myers Squibb Paid Holidays 106 employees reported this benefit 4.3 20 Ratings Available to US-based employees Change location Employee Comments Showing 1-10 of 20 28 Jan 2023 4.0 Current Direcror in nullnull Comparable to many others in the same league Helpful Report 22 Dec 2022 4.0 Our mission to enhance the lives of patients requires an investment in a strong learning culture. 0000010800 00000 n Many of these vary by location, such as: If you're interested in advancing your career with an innovative team, join our Talent Community to keep in touch about the latest news and opportunities that match your interests. Apr 2021 - Oct 2022 1 year 7 months. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. The effective tax benefit rate was 27.7% in the quarter. The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. 3 floating holidays. An effective tax rate of approximately 24% for GAAP and approximately 16.5% for non-GAAP. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. LICENSE AGREEMENT. Monday Jan 11, 2021 07:30 AM ET. Bristol-Myers Squibb, one of the world's largest pharmaceutical companies, arose out of a 1989 merger and today focuses on the manufacture of prescription medicines for the treatment of cancer . Additional Information about the Tender Offer and Where to Find it. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . Choosing Your Medical Plan. When you join one of our diverse, high-achieving teams, youll collaborate each day to help transform the lives of patients around the world. Here we feature several BMS colleagues sharing their views on the subject from their perspectives, based on their own experiences. Minor Fasts . (( g Virtual Benefits Fair. Top 50%. ET during which company executives will review financial information and address inquiries from investors and analysts. Show more Show less Resident Advisor Bucknell University . 0000005253 00000 n This led to the automatic termination of the CVR agreement Jan. 1,2021 rendering the CVRs as ineligible for payment under the agreement. Learn about joining our global team! Learn more! General and technical inquiries. We incent, recognize, reward and celebrate those who consistently embody our mission and behaviors to reach above and beyond, driving our business forward. Headquarters Location 430 E. 29th Street 14th Floor New York, New York, 10016, United States 0000006923 00000 n "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow." Senior Research Investigator salaries ($93k), Research Investigator II salaries ($108k), Associate Research Scientist I salaries ($70k), Senior Research Investigator II salaries ($132k), Associate Research Scientist II salaries ($77k). 0000193195 00000 n Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets, said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. Supervised Warehouse staff. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. Percentages and earnings per share amounts presented are calculated from the underlying amounts. A cash dividend payment of $0.49 per share is scheduled to be paid on August 02, 2021. We incorporate security and human rights in our assessment of countries when determining where to locate operating facilities. Our broad range of benefits opportunities can enrich your total rewards experience and financial readiness to take on whatever is next in your life: Our paid vacation and holidays give you the flexibility to take time off to recharge and return refreshed and invigorated to deliver your best: Theres more to a healthy person than a healthy body. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Media and Investor Relations: ir@tptherapeutics.com, Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. 0000001396 00000 n Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. With support and coaching from your colleagues, youre encouraged to take on stretch assignments that maximize your learning experience. We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. (link). (PDF), UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. 0000002184 00000 n The companys pipeline of precision oncology drug candidates is being studied across a variety of solid tumors. Bristol Myers Squibb will not tolerate practices that violate the intent of our Mission and Commitment. 0000004547 00000 n The website may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. 866 0 obj No matter the role within BMS, we all embrace a patient-centric culture. they used to have flexible schedules- though that is unfortunately being phased out. 813 55 Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. 3 floating holidays. In 2021, their top products included Revlimid and Opdivo, drugs used in the treatment of certain. Privacy Protection The FDA has accepted the NDA and the EMA has validated the Marketing Authorization Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. Past events. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect Bristol Myers Squibbs business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibbs Annual Report on Form 10-K for the year ended December 31, 2021, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in Turning Point Therapeutics Annual Report on Form 10-K for the year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q , as well as other documents that may be filed by Bristol Myers Squibb or Turning Point Therapeutics from time to time with the SEC. Bristol-Myers is Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: 21-04897. 0000007092 00000 n As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. Cautionary Statement Regarding Forward-Looking Statements. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. In addition, the non-GAAP financial guidance in this communication excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. You may read any reports, statements or other information filed by the company or Turning Point Therapeutics with the SEC at no charge on the SECs website at www.sec.gov. <>z{^)P"PPq@ 6/ View this presentation. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. 0000002778 00000 n Manage cover for holidays and absenteeism for warehouse staff through Time Management. We expect our contractors and suppliers to comply with all legal and regulatory requirements for the workplace, including health and safety, diversity and human rights. All of our employees must comply with the highest standards of data privacy protection consistent with the laws of the jurisdiction in which they operate. June 08, 2022 06:59 AM Eastern Daylight Time. I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. Shareholders who. Tuition reimbursement is available to eligible employees who, through their own initiation and desire for development, participate in accredited educational programs that their manager deems will be mutually beneficial to BMS and the employee. Investors and the public can also access the live webcast by dialing in the U.S. toll free 877-502-9276 or international +1 313-209-4906, confirmation code: 2150568. U.S. revenues increased 11% to $7.5 billion in the quarter. 0000042788 00000 n Research and development expenses decreased 30% to $2.6 billion in the quarter. Expects low- to mid-single digit revenue CAGR and low double-digit revenue CAGR for our Continuing Business, Expects to maintain low- to mid-40s percent non-GAAP operating margin, Expects significant free cash flow generation of $45-$50 billion dollars from 2022-2024. #BMSCareers. Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. The transaction is expected to be up to $0.08 per share dilutive to non-GAAP EPS in 2022 prior to any impact from an acquired in-process research and development charge based on final accounting treatment. Posted: October 12, 2021 Full-Time At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. Toggle Dropdown. The Bristol-Myers Squibb Benefits Program gives you the flexibility and opportunity to choose from a variety of options. Materials on this website may contain information about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. A method of treating a disorder mediated by BRD9 comprising administering an effective amount of a compound of Formula: or a pharmaceutically acceptable salt thereof July 28 (Reuters) - Bristol Myers Squibb Co (BMY.N) reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after. bristol myers squibb Dublin, Ireland . The stock was sold at an average price of $64.21, for a total transaction of $200,270.99. Tuesday, November 16, 2021. Investor Relations: investor.relations@bms.com The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication. The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset, said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Use of Non-GAAP Financial Information and Financial Guidance, In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). 0000006494 00000 n Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. They merged in 1989, creating a powerhouse pharmaceutical company that was the second-largest in the world at the time. ***Included as part of the key loss of exclusivity (LOE) brands, *In excess of +100%. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. The company was founded in 1887 and is based in New York, New York. Kitchenettes with vending machines, free coffee and tea. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. On-site services depending on location, such as Federal Credit Union, dry cleaning, automobile detailing and massage therapy. FOURTH QUARTER PRODUCT REVENUE HIGHLIGHTS, *In excess of +100%. Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. There are regular US holidays with 4 floating holiday/personal days. Media: media@bms.com Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges or other income resulting from up-front or contingent milestone payments in connection with the acquisition or licensing of third-party intellectual property rights, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. (Reuters) - A judge in Hawaii on Monday ordered Bristol-Myers Squibb (NYSE: BMY) Co and Sanofi (NASDAQ: SNY) SA Following the sale, the senior vice president now directly owns 16,243 shares in the company, valued at $1,042,963.03.